Back to top
more

Axsome Therapeutics (AXSM)

(Delayed Data from NSDQ)

$71.71 USD

71.71
272,230

+0.19 (0.27%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $71.76 +0.05 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Axsome (AXSM) Up 26.9% Since Last Earnings Report?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XPH

Axsome (AXSM) up 118.4% in the Past Three Months: Here's Why

by Zacks Equity Research

Axsome (AXSM) surges in the past three months owing to its Sunosi acquisition and promising progress on its pipeline candidate.

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07

by Zacks Equity Research

Axsome (AXSM) initiates a phase III open-label study for its pipeline candidate, AXS-07 for treating acute migraine.

Biotech Stock Roundup: GILD, BLUE, AXSM's Drug Approvals, FHTX Study Update & More

by Zacks Equity Research

Regulatory updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.

Axsome (AXSM) Soars on FDA Nod for Depression Drug, Auvelity

by Zacks Equity Research

The FDA approves Axsome's (AXSM) Auvelity extended-release tablets for the treatment of major depressive disorder in adults. This becomes the first approved product for the company. Shares rise.

Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss

by Zacks Equity Research

Axsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company records its first sales of the sleep drug, Sunosi, which it acquired from Jazz.

Axsome Therapeutics (AXSM) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Axsome (AXSM) delivered earnings and revenue surprises of 10.92% and 8.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug, Biotech Stocks' Q2 Earnings on Aug 9: EXEL, BHC & More

by Kinjel Shah

Let us look at four drug and biotech companies, EXEL, BHC, CPRX and AXSM, which are gearing up for their earnings release.

Jazz's (JAZZ) Q2 Earnings Beat, New Drugs Post Robust Sales

by Zacks Equity Research

JAZZ's Q2 earnings and sales beat expectations on strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. The company affirms its 2022 guidance.

HighPeak (HPK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Higher commodity prices are expected to have aided HighPeak's (HPK) bottom line in Q2.

Axsome (AXSM) Hurt by Regulatory Setbacks: Will It Recover?

by Zacks Equity Research

Axsome's (AXSM) extension of the review period for AXS-05 NDA and CRL for AXS-07 NDA hurt prospects. However, recent positive updates on AXS-05 are driving positive sentiments.

JAZZ's Late-Stage Multiple Sclerosis Study on Nabiximols Fails

by Zacks Equity Research

JAZZ's phase III study evaluating nabiximols oromucosal spray for clinical measures of spasticity in multiple sclerosis patients fails to meet the primary endpoint.

Axsome (AXSM) Surges Following FDA Label Proposal for AXS-05

by Zacks Equity Research

Axsome (AXSM) receives proposed labeling from the FDA for its under-review depression drug candidate, AXS-05, implying a potential approval soon. Shares surge more than 50%.

Halozyme Therapeutics (HALO) Up 19.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Axsome (AXSM) Down 30.3% Since Last Earnings Report?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

JAZZ Q1 Earnings Miss, Sales Robust, 2022 Guidance Raised

by Zacks Equity Research

JAZZ's product revenues grow in the first quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. It raises guidance on strong results.

Why Axsome (AXSM) is Up 7% Despite Wider-Than-Expected Q1 Loss

by Zacks Equity Research

Axsome (AXSM) reports a slightly wider-than-estimated Q1 loss. It expects to receive FDA approval for its lead candidate AXS-05 by second-quarter 2022 to treat major depressive disorder.

Biotech Stock Roundup: GILD's COVID-19 Drug Update, AXSM Down on Regulatory News

by Zacks Equity Research

Regulatory and pipeline updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.

JAZZ Stock Surges Almost 30% YTD: What's Driving the Rally?

by Zacks Equity Research

Strong performance of JAZZ's Xywav and new oncology drugs along with acquired drugs reduced dependence on Xyrem, which will face generic competition shortly.

Biotech Stock Roundup: NKTR Plunges on Deal Termination, REGN Offers Update & More

by Zacks Equity Research

Regulatory and pipeline updates from Nektar (NKTR) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

Axsome (AXSM) Surges on Potential Approval for AXS-05 Soon

by Zacks Equity Research

The FDA provides post-marketing requirements/commitments related to Axsome's (AXSM) under-review NDA for its lead pipeline candidate, AXS-05, for treating MDD. Investors anticipate an approval shortly.

Axsome (AXSM) Up 27.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: AXSM to Acquire JAZZ's Drug, IGMS Up on SNY Deal & More

by Zacks Equity Research

Acquisition and collaboration news from Axsome (AXSM) and IGM Biosciences, Inc. (IGMS), respectively, are a few key highlights from the biotech sector during the past week.